Clinical Trials Logo

Clinical Trial Summary

This research study is for subjects with squamous cell cancer of the head and neck which is not solely treatable with surgery or radiation. This research study involves treatment with an experimental chemotherapy combination of oxaliplatin and Taxotere. Tha main purpose of this study is to assess the effectiveness of this combination of medications for this type of cancer.

Approximately 54 subjects will take part in this study.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00184028
Study type Interventional
Source University of Southern California
Contact
Status Terminated
Phase Phase 2
Start date September 2004
Completion date July 2010

See also
  Status Clinical Trial Phase
Withdrawn NCT00257335 - Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer Phase 2
Completed NCT00865098 - Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase 2
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Completed NCT03733210 - Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer Phase 1
Recruiting NCT03001570 - Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District Phase 2
Completed NCT02626000 - Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) Phase 1
Completed NCT00050388 - Phase II Trial of Allovectin-7® for Head and Neck Cancer Phase 3